Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a globally diversified conglomerate based in Washington, D.C., focusing primarily on life sciences and diagnostics. Founded in 1984 by Stephen and Mitchell Rales, the company has transitioned from a real estate organization into a leading player in the medical, industrial, and commercial products sectors.
Danaher designs, manufactures, and markets a variety of innovative products, particularly scientific instruments and consumables. The company has recently revamped its portfolio by divesting its environmental and applied solutions group, Veralto, in late 2023. This strategic move has allowed Danaher to concentrate its efforts on advancing health through science and technology.
Among Danaher's notable achievements is the acquisition of Abcam plc, which enhances its capabilities in proteomics—an expanding field within life sciences. The company is also known for its contribution to gene-editing therapies through a collaboration with the Innovative Genomics Institute (IGI), aiming to develop CRISPR-based treatments for various diseases.
Danaher's portfolio includes well-known subsidiaries like Beckman Coulter Life Sciences, Integrated DNA Technologies, and Aldevron. These subsidiaries focus on delivering innovative solutions in diagnostics, genomics, and biomanufacturing. For instance, Beckman Coulter's recent partnership with Curiox Biosystems aims to provide automated sample preparation for flow cytometry, enhancing research efficiency.
Financially, Danaher reported better-than-expected revenue in the fourth quarter of 2023, bolstered by strong performance in its life sciences and diagnostics segments. The company's strategic divestitures and acquisitions have positioned it for long-term growth and increased shareholder value.
Danaher’s ongoing projects include a collaboration with Cincinnati Children's Hospital to improve liver organoid technology for drug toxicity screening. This initiative is part of the Danaher Beacons program, which funds pioneering academic research to develop next-generation medical technologies. Another significant collaboration is with Johns Hopkins University, focusing on diagnosing mild traumatic brain injuries (TBI) using advanced biomarker panels.
Overall, Danaher's commitment to scientific excellence, innovation, and continuous improvement makes it a crucial player in advancing healthcare globally. With over 63,000 associates worldwide, Danaher is dedicated to improving quality of life and laying the groundwork for a healthier, more sustainable future.
Beckman Coulter has launched its Access SARS-CoV-2 Immunoglobulin M (IgM) assay in CE Mark countries. The test exhibits 99.9% specificity and 98.3% sensitivity 15-30 days post-symptom onset, offering a positive predictive value of 95.5% in populations with a 3% disease incidence. This assay complements Beckman Coulter's suite of COVID-19 testing solutions, which include IgG assays and an antigen test under development. Beckman Coulter aims to address high testing demands by leveraging its advanced automation technology, capable of delivering over 15 million tests monthly.
Cytiva has launched new services aimed at supporting point-of-care diagnostic developers, enhancing speed to market for new tests. The initiative includes establishing new labs in Germany and China, and expanding existing facilities in Wales. A multi-million dollar investment will boost diagnostic capabilities and supply chain enhancements. Cytiva has played a pivotal role during the COVID-19 pandemic, aiding the testing of over 50 million individuals. This investment is part of a broader $500 million plan to expand manufacturing capacity over five years.
Danaher Corporation (NYSE: DHR) reported strong financial results for Q3 2020, with net earnings of $883.5 million ($1.16 per diluted share), up 38% year-over-year. Non-GAAP adjusted earnings per share increased by 62% to $1.72. Revenues rose 34.5% to $5.9 billion, with core revenue growth at 14%. Operating cash flow surged 93% to $1.7 billion, and free cash flow increased by 110% to $1.5 billion. The company anticipates low-double digit revenue growth for Q4 2020, emphasizing its resilience and commitment to addressing COVID-19 challenges.
Beckman Coulter announced on Oct. 15, 2020, that it received funding from the Biomedical Advanced Research and Development Authority (BARDA) for a multi-center clinical trial validating the Monocyte Distribution Width (MDW) biomarker. This biomarker aids in the rapid detection of Multisystem Inflammatory Syndrome in Children (MIS-C), a severe complication of COVID-19. The funding will support collaboration with Massachusetts General Hospital, Johns Hopkins University, and the University of Florida.
Beckman Coulter announced that its Access SARS-CoV-2 Immunoglobulin M (IgM) assay has received Emergency Use Authorization (EUA) from the U.S. FDA. The assay detects IgM antibodies with 99.9% specificity and 98.3% sensitivity, aiding in COVID-19 diagnostics. This product is part of a broader suite of COVID-19 testing solutions, which includes the previously authorized IgG assay and an IL-6 assay for severe inflammatory responses. Beckman Coulter is also developing a SARS-CoV-2 antigen assay and a quantitative IgG assay, showing its commitment to advancing healthcare.
Danaher Corporation (NYSE: DHR) will host a webcast of its third quarter 2020 earnings conference call on October 22, 2020, at 8:00 a.m. ET, lasting approximately one hour. The call can be accessed via Danaher's website under the 'Investors' section. A replay will be available after the call until November 5, 2020. The earnings press release, along with related materials, will be posted at 6:00 a.m. ET on the call date. Danaher focuses on innovative science and technology solutions in healthcare and environmental sectors.
On October 6, 2020, Danaher Corporation (NYSE:DHR) announced the redemption of all €800,000,000 1.700% Senior Notes due 2022. The redemption will occur on November 5, 2020, at a price equal to the principal amount plus a make-whole premium and accrued interest. Funding for this redemption will come from the proceeds of a recent senior notes offering. Danaher continues to focus on innovation across healthcare and environmental markets with over 67,000 associates globally.
Danaher Corporation (NYSE: DHR) announced the pricing of a $1 billion offering of senior notes with a 2.600% interest rate due in 2050. The offering price is 98.970% of the principal amount, with expected net proceeds of approximately $980 million after expenses. Funds will be used for general corporate purposes, including refinancing debt and capital expenditures. The offering is set to close on October 6, 2020, pending customary conditions.
Cepheid has received Emergency Use Authorization (EUA) from the FDA for its new Xpert® Xpress SARS-CoV-2/Flu/RSV test, which detects COVID-19, Flu A, Flu B, and RSV from a single sample. This test, operational on over 26,000 GeneXpert® Systems worldwide, delivers results in approximately 36 minutes. Supported by a capacity expansion program from parent company Danaher Corporation (DHR), Cepheid aims to meet increasing demand. Shipping to U.S. customers is set to begin this week, with CE-IVD availability expected in November.
Danaher Corporation (NYSE: DHR) has corrected the quarterly cash dividend for its 5.00% Series B Mandatory Convertible Preferred Stock. The revised dividend will be $12.50 per share, payable on October 15, 2020, to shareholders on record as of September 30, 2020. This adjustment ensures clarity on the Company’s commitment to its investors and reflects stable financial management.
FAQ
What is the current stock price of Danaher Corporation (DHR)?
What is the market cap of Danaher Corporation (DHR)?
What does Danaher Corporation specialize in?
Who founded Danaher Corporation and when?
Where is Danaher Corporation headquartered?
What recent divestiture has Danaher Corporation made?
What are some of Danaher's notable subsidiaries?
What recent acquisition has enhanced Danaher's capabilities in proteomics?
What is the Danaher Beacons program?
What collaboration is Danaher involved in to improve liver organoid technology?
What is the focus of Danaher's partnership with Johns Hopkins University?
How does Danaher contribute to the field of gene-editing therapies?
